CLRB – Cellectar Biosciences Inc.
CLRB — Price & Forward EBITDA
Forward EBITDA (M)
Float Short %
1.15
Margin Of Safety %
Put/Call OI Ratio
EPS Next Q Diff
-0.52
EPS Last/This Y
4.16
EPS This/Next Y
1.1
Price
2.72
Target Price
12
Analyst Recom
1
Performance Q
-2.17
Upside
-13,503.7%
Beta
0.35
Ticker: CLRB
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-02-27 | CLRB | 3.26 | N/A | N/A | 0 |
| 2026-03-02 | CLRB | 3.01 | N/A | N/A | 0 |
| 2026-03-03 | CLRB | 2.7711 | N/A | N/A | 0 |
| 2026-03-04 | CLRB | 2.86 | N/A | N/A | 0 |
| 2026-03-05 | CLRB | 2.76 | N/A | N/A | 0 |
| 2026-03-06 | CLRB | 2.75 | N/A | N/A | 0 |
| 2026-03-09 | CLRB | 2.72 | N/A | N/A | 0 |
| 2026-03-10 | CLRB | 3.05 | N/A | N/A | 0 |
| 2026-03-11 | CLRB | 2.95 | N/A | N/A | 0 |
| 2026-03-12 | CLRB | 3.27 | N/A | N/A | 0 |
| 2026-03-13 | CLRB | 3.23 | N/A | N/A | 0 |
| 2026-03-17 | CLRB | 3.34 | N/A | N/A | 0 |
| 2026-03-18 | CLRB | 3.2 | N/A | N/A | 0 |
| 2026-03-19 | CLRB | 3.18 | N/A | N/A | 0 |
| 2026-03-20 | CLRB | 3.21 | N/A | N/A | 0 |
| 2026-03-23 | CLRB | 3.1 | N/A | N/A | 0 |
| 2026-03-24 | CLRB | 3.05 | N/A | N/A | 0 |
| 2026-03-25 | CLRB | 2.98 | N/A | N/A | 0 |
| 2026-03-26 | CLRB | 2.91 | N/A | N/A | 0 |
| 2026-03-27 | CLRB | 2.72 | N/A | N/A | 0 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-02-27 | CLRB | 3.25 | -306.7 | - | -8.92 |
| 2026-03-02 | CLRB | 3.03 | -306.7 | - | -8.92 |
| 2026-03-03 | CLRB | 2.70 | -306.7 | - | -8.92 |
| 2026-03-04 | CLRB | 2.90 | -306.7 | - | -8.92 |
| 2026-03-05 | CLRB | 2.75 | -306.7 | - | -8.92 |
| 2026-03-06 | CLRB | 2.78 | -306.7 | - | -8.92 |
| 2026-03-09 | CLRB | 2.81 | 72.7 | - | -4.15 |
| 2026-03-10 | CLRB | 3.09 | 72.7 | - | -4.15 |
| 2026-03-11 | CLRB | 2.94 | 72.7 | - | -4.15 |
| 2026-03-12 | CLRB | 3.20 | 72.7 | - | -4.15 |
| 2026-03-13 | CLRB | 3.25 | 67.9 | - | -5.54 |
| 2026-03-17 | CLRB | 3.34 | 55.1 | - | -4.20 |
| 2026-03-18 | CLRB | 3.21 | 55.1 | - | -4.20 |
| 2026-03-19 | CLRB | 3.16 | 55.1 | - | -4.20 |
| 2026-03-20 | CLRB | 3.14 | 55.1 | - | -4.20 |
| 2026-03-23 | CLRB | 3.11 | 55.1 | - | -4.20 |
| 2026-03-24 | CLRB | 3.05 | 55.1 | - | -4.20 |
| 2026-03-25 | CLRB | 2.99 | 55.1 | - | -4.20 |
| 2026-03-26 | CLRB | 2.97 | 55.1 | - | -4.20 |
| 2026-03-27 | CLRB | 2.72 | 55.1 | - | -4.20 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-02-27 | CLRB | -0.08 | 6.73 | 2.94 |
| 2026-03-02 | CLRB | -0.08 | 6.76 | 2.94 |
| 2026-03-03 | CLRB | -0.08 | 6.76 | 2.94 |
| 2026-03-04 | CLRB | -0.08 | 6.76 | 2.94 |
| 2026-03-05 | CLRB | -0.08 | 6.76 | 2.94 |
| 2026-03-06 | CLRB | -0.08 | 6.76 | 2.94 |
| 2026-03-09 | CLRB | -0.08 | 6.71 | 2.94 |
| 2026-03-10 | CLRB | -0.08 | 6.71 | 2.94 |
| 2026-03-11 | CLRB | -0.08 | 6.71 | 2.26 |
| 2026-03-12 | CLRB | -0.08 | 6.71 | 2.26 |
| 2026-03-13 | CLRB | -0.08 | 6.71 | 2.26 |
| 2026-03-17 | CLRB | -0.08 | 6.71 | 2.26 |
| 2026-03-18 | CLRB | -0.08 | 6.71 | 2.26 |
| 2026-03-19 | CLRB | -0.08 | 6.71 | 2.26 |
| 2026-03-20 | CLRB | -0.08 | 6.71 | 2.26 |
| 2026-03-23 | CLRB | -0.08 | 6.71 | 2.26 |
| 2026-03-24 | CLRB | -0.08 | 6.71 | 2.26 |
| 2026-03-25 | CLRB | -0.08 | 6.71 | 1.15 |
| 2026-03-26 | CLRB | -0.08 | 6.71 | 1.15 |
| 2026-03-27 | CLRB | -0.08 | 6.71 | 1.15 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.53
Avg. EPS Est. Current Quarter
-1.89
Avg. EPS Est. Next Quarter
-1.05
Insider Transactions
-0.08
Institutional Transactions
6.71
Beta
0.35
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
4
Growth Score
19
Sentiment Score
2
Actual DrawDown %
99.5
Max Drawdown 5-Year %
-99.5
Target Price
12
P/E
Forward P/E
PEG
P/S
P/B
1.43
P/Free Cash Flow
EPS
-10.34
Average EPS Est. Cur. Y
-4.2
EPS Next Y. (Est.)
-3.1
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
0.46
Return on Equity vs Sector %
-282.6
Return on Equity vs Industry %
-266.3
EPS 1 7Days Diff
4
EPS 1 30Days Diff
3.32
EBIT Estimation
◆
CLRB
Healthcare
$2.70
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
37
Range 1M
10.4%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
52.3%
EPS NY
23.5%
52W%
1.5%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+344.4% upside
Upside
+344.4%
Quality
4
Cellectar Biosciences, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 11
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer in the United States. The company's lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r head and neck cancer. It also develops CLR125, an iodine-125 Auger-emitting radioconjugate program; and CLR 225, an actinium-225 based program. The company has collaborative with Orano Med to develop alpha emitter lead-212 conjugated to phospholipid ether series; and LegoChem Bio. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Florham Park, New Jersey.
CLRB
Latest News
—
Caricamento notizie per CLRB…
stock quote shares CLRB – Cellectar Biosciences Inc. Stock Price stock today
news today CLRB – Cellectar Biosciences Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch CLRB – Cellectar Biosciences Inc. yahoo finance google finance
stock history CLRB – Cellectar Biosciences Inc. invest stock market
stock prices CLRB premarket after hours
ticker CLRB fair value insiders trading